Real-World Study of Apatinib in the Treatment of Advanced Lung Cancer

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800018113

Enrollment

Unknown

Registered

2018-08-31

Start date

2018-10-15

Completion date

Unknown

Last updated

2018-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

Case series:Apatinib mesylate

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age 18~75 years; 2. Pathological or histologically diagnosed as advanced (IIIB; Stage IV) lung cancer patients; 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2; 4. Survival expectation= 3 months; 5. Patients with indications for treatment and no contraindications to chemotherapy; 6. The main organ function is generally normal, or can be tolerated by apatinib according to the judgment of the clinician; 7. Researchers believe that treatment has survival benefits.

Exclusion criteria

Exclusion criteria: 1. Allergic to apatinib mesylate tablets and/or their excipients; 2. Pregnant or lactating females; 3. Patients with contraindications to apatinib; 4. Researchers believe that it is not suitable for inclusion.

Design outcomes

Primary

Measure	Time frame
Tumor diameter;	—

Countries

China

Contacts

Public ContactHuang Cheng

Fujian Provincial Cancer Hospital

cheng671@sina.com+86 13905010379

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026